查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1608108

感染疾病疫苗市场：副产品、感染疾病和最终用户 - 全球预测 2025-2030

Infectious Vaccines Market by Product (Preventive Vaccine, Therapeutic Vaccine), Infectious Disease (Allergy, Cervical Cancer, DTP), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年感染疾病疫苗市场估值为300.1亿美元，预计2024年将达318.3亿美元，复合年增长率为8.98%，到2030年将达到548.3亿美元。

感染疾病疫苗是透过刺激人体免疫反应，提供针对各种感染疾病的免疫力的生技药品。对感染疾病疫苗的需求至关重要，因为它们在预防疾病爆发、降低发病率和死亡率以及实现群体免疫方面发挥着重要作用。这些疫苗的应用涵盖针对流感、肝炎、麻疹和 COVID-19 等疾病的公共卫生计划、个人化免疫接种和全球健康倡议。最终用途包括政府卫生部门、医院、诊所和研究机构，所有这些机构都将疫苗用于大规模免疫宣传活动和个人化预防护理。影响感染疾病疫苗市场的关键成长要素包括预防医学意识的提高、疫苗开发的技术进步、政府的免疫措施以及对疫苗研究的大力资助。新兴市场开拓的驱动力是新疫苗的开发，例如基于mRNA的疫苗和多效价疫苗，它们在大流行期间和针对快速变异的病毒具有潜力。公司可以透过投资研究并与政府和非政府组织建立合作伙伴关係来扩大疫苗分销网络，从而利用这些机会。然而，市场面临着可能阻碍其成长的限制和挑战，例如高昂的研发成本、严格的法律规范和疫苗犹豫不决。促进成长的创新领域包括个人化疫苗、减少低温运输挑战的耐热疫苗以及提高易用性的无针输送系统。市场洞察也指出，疫苗分发和监测将转向数位平台，这可以优化供应链和接种后后续工作。市场动态是动态和竞争的，需要不断创新并适应不断变化的公共卫生环境和新出现的疾病。

主要市场统计
基准年[2023] 300.1亿美元
预测年份 [2024] 318.3亿美元
预测年份 [2030] 548.3亿美元
复合年增长率（%） 8.98%

市场动态：揭示快速发展的感染疾病疫苗市场的关键市场洞察

供需的动态交互作用正在改变感染疾病疫苗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 爱滋病毒、癌症和糖尿病等慢性病盛行率高
    • 控制流行病的政府优先活动
    • 提高消费者的健康意识和支出
  • 市场限制因素
    • 疫苗生产高成本、工期长
  • 市场机会
    • 公共和私人研发投资的增加
    • 采用新型感染疾病疫苗
  • 市场问题
    • 疫苗的潜在副作用和不利事件

波特五力：引领感染疾病疫苗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解感染疾病疫苗市场的外部影响

外部宏观环境因素对感染疾病疫苗市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解感染疾病疫苗市场竞争状况

感染疾病疫苗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵：感染疾病疫苗市场供应商绩效评估

FPNV定位矩阵是评估感染疾病疫苗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製感染疾病疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，感染疾病疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 爱滋病毒、癌症和糖尿病等慢性病的盛行率很高
      • 控制传染病的政府优先活动
      • 提高消费者的健康意识和支出
    • 抑制因素
      • 疫苗生产成本高、週期长
    • 机会
      • 增加公营和私营部门对研发的投资
      • 采用新型感染疾病疫苗
    • 任务
      • 疫苗的潜在副作用和不利事件
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章感染疾病疫苗市场：副产品

  • 介绍
  • 预防性疫苗
  • 治疗性疫苗

第七章感染疾病疫苗市场：依感染疾病

  • 介绍
  • 过敏
  • 子宫颈癌
  • DTP
  • 肝炎
  • 流感
  • 脑膜炎奈瑟菌
  • MMR
  • 肺炎球菌
  • 脊髓灰质炎
  • 轮状病毒
  • 水痘

第八章感染疾病疫苗市场：依最终用户分类

  • 介绍
  • 成人
  • 儿科的

第九章 北美、南美感染疾病疫苗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太感染疾病疫苗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东、非洲感染疾病疫苗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat BIoTech
  • Biological E Ltd.
  • CSL Limited
  • DAIICHI SANKYO COMPANY, LIMITED
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Incepta Vaccine, Ltd.
  • Johnson and Johnson Services Inc.
  • Lonza Group AG
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Novavax, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt., Ltd
  • Sinovac BIoTech Ltd.
Product Code: MRR-ED54C46E8F6D

The Infectious Vaccines Market was valued at USD 30.01 billion in 2023, expected to reach USD 31.83 billion in 2024, and is projected to grow at a CAGR of 8.98%, to USD 54.83 billion by 2030.

Infectious vaccines are biological preparations that provide immunity against various infectious diseases by stimulating the body's immune response. The necessity for infectious vaccines is paramount due to their critical role in preventing disease outbreaks, reducing morbidity and mortality, and achieving herd immunity. The application of these vaccines spans public health programs, individual immunizations, and global health initiatives targeting diseases such as influenza, hepatitis, measles, and COVID-19. The end-use scope includes government healthcare departments, hospitals, clinics, and research institutions, all of which utilize vaccines for mass immunization campaigns and individual preventive care. Key growth factors influencing the infectious vaccines market include increasing awareness of preventive healthcare, technological advancements in vaccine development, government initiatives for immunization, and the robust funding for vaccine research. Emerging opportunities in the market are driven by the development of novel vaccines, such as mRNA-based vaccines and multi-valent vaccines, which offer potential during pandemics or against rapidly mutating viruses. Companies can capitalize on these opportunities by investing in research and securing partnerships with governmental and non-governmental organizations to expand vaccine distribution networks. However, the market faces limitations and challenges such as high R&D costs, stringent regulatory frameworks, and vaccine hesitancy among populations, which can inhibit market growth. Innovative areas for growth include personalized vaccines, thermostable vaccines that mitigate cold chain challenges, and needle-free delivery systems that enhance ease of use. Market insights also indicate a shift towards digital platforms for vaccine distribution and monitoring, which can optimize supply chains and post-vaccination follow-ups. The nature of the infectious vaccines market is dynamic and highly competitive, necessitating continuous innovation and adaptation to changing public health environments and emerging diseases.

KEY MARKET STATISTICS
Base Year [2023] USD 30.01 billion
Estimated Year [2024] USD 31.83 billion
Forecast Year [2030] USD 54.83 billion
CAGR (%) 8.98%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infectious Vaccines Market

The Infectious Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High prevalence of chronic diseases including HIV, cancer, diabetes
    • Government focused activities to control epidemic diseases
    • Rising consumer awareness and expenditure regarding health
  • Market Restraints
    • High costs and longer timelines required for vaccine production
  • Market Opportunities
    • Growing investment by public & private sector for R&D endeavors
    • Introduction of novel infectious vaccines
  • Market Challenges
    • Possibilities of vaccine side effects and adverse events

Porter's Five Forces: A Strategic Tool for Navigating the Infectious Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infectious Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infectious Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infectious Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infectious Vaccines Market

A detailed market share analysis in the Infectious Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infectious Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infectious Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Infectious Vaccines Market

A strategic analysis of the Infectious Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Infectious Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma, Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech, Biological E Ltd., CSL Limited, DAIICHI SANKYO COMPANY, LIMITED, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Vaccine, Ltd., Johnson and Johnson Services Inc., Lonza Group AG, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Novavax, Inc., Pfizer, Inc., Sanofi SA, Serum Institute of India Pvt., Ltd, and Sinovac Biotech Ltd..

Market Segmentation & Coverage

This research report categorizes the Infectious Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Preventive Vaccine and Therapeutic Vaccine.
  • Based on Infectious Disease, market is studied across Allergy, Cervical Cancer, DTP, Hepatitis, Influenza, Meningococcal, MMR, Pneumococcal, Polio, Rotavirus, and Varicella.
  • Based on End User, market is studied across Adults and Pediatrics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of chronic diseases including HIV, cancer, diabetes
      • 5.1.1.2. Government focused activities to control epidemic diseases
      • 5.1.1.3. Rising consumer awareness and expenditure regarding health
    • 5.1.2. Restraints
      • 5.1.2.1. High costs and longer timelines required for vaccine production
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing investment by public & private sector for R&D endeavors
      • 5.1.3.2. Introduction of novel infectious vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Possibilities of vaccine side effects and adverse events
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Infectious Vaccines Market, by Product

  • 6.1. Introduction
  • 6.2. Preventive Vaccine
  • 6.3. Therapeutic Vaccine

7. Infectious Vaccines Market, by Infectious Disease

  • 7.1. Introduction
  • 7.2. Allergy
  • 7.3. Cervical Cancer
  • 7.4. DTP
  • 7.5. Hepatitis
  • 7.6. Influenza
  • 7.7. Meningococcal
  • 7.8. MMR
  • 7.9. Pneumococcal
  • 7.10. Polio
  • 7.11. Rotavirus
  • 7.12. Varicella

8. Infectious Vaccines Market, by End User

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Pediatrics

9. Americas Infectious Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Infectious Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Infectious Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astellas Pharma, Inc.
  • 3. AstraZeneca PLC
  • 4. Bavarian Nordic A/S
  • 5. Bharat Biotech
  • 6. Biological E Ltd.
  • 7. CSL Limited
  • 8. DAIICHI SANKYO COMPANY, LIMITED
  • 9. Emergent BioSolutions Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Incepta Vaccine, Ltd.
  • 12. Johnson and Johnson Services Inc.
  • 13. Lonza Group AG
  • 14. Merck & Co., Inc.
  • 15. Mitsubishi Tanabe Pharma Corporation
  • 16. Novartis International AG
  • 17. Novavax, Inc.
  • 18. Pfizer, Inc.
  • 19. Sanofi SA
  • 20. Serum Institute of India Pvt., Ltd
  • 21. Sinovac Biotech Ltd.

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. INFECTIOUS VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFECTIOUS VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFECTIOUS VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PREVENTIVE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY THERAPEUTIC VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MMR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 153. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2023